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Abstract
From September 2003 to December 2005, 188 patients who visited our hospital and allied
institutions for the purpose of prostate brachytherapy were administrated hormonal therapy for
volume reductions before brachytherapy. The pretreatment and posttreatment of prostate volume
using a transrectal ultrasound volumetric study and the types and duration of hormonal therapy
were analyzed. We administered 91 patients with Luteinizing hormone-releasing hormone (LH-
RH) agonist, 49 patients with anti-androgen (bicaltamide/flutamide), and 48 patients with max-
imum androgen blockade (MAB). The duration of the hormonal therapy was 1-3 months for 49
patients, 4-6 months for 59 patients, 7-9 months for 40 patients, 10-12 months for 32 patients, and
over 13 months for 8 patients. Before the initiation of hormonal therapy, the mean prostate volume
was 35.12 ml (11.04-78.71 ml), and the average of prostate volume before and after hormonal ther-
apy was 36.79 ml and 24.79 ml, respectively (a 32.4% reduction). The prostate volume reduction
rate was 32.0% for the LH-RH agonist only, 18.1% for the anti-androgen only and 41.2% for the
MAB. No statistically significant difference was observed for the duration of hormonal therapy
between 3 groups. A three-month course of the neoadjuvant LH-RH agonist indicated a sufficient
volume reduction effectiveness for a large prostate volume.
KEYWORDS: androgen deprivation therapy, brachytherapy, localized prostate cancer, prostate
volume reduction
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n the past decade,  the results of clinical trials 
in men treated with a combination of androgen 
deprivation therapy (ADT) and external-beam radio-
therapy (EBRT) have demonstrated a signiﬁ cant ben-
eﬁ t [1ﾝ3].  As a result,  ADT is increasingly used in 
combination with prostate brachytherapy.  In Japan,  
the use of an iodine-125 (I-125) seed source was 
approved legally in July 2003,  and over 1,000 
I
From September 2003 to December 2005,  188 patients who visited our hospital and allied institutions 
for the purpose of prostate brachytherapy were administrated hormonal therapy for volume reduc-
tions before brachytherapy.  The pretreatment and posttreatment of prostate volume using a transrec-
tal ultrasound volumetric study and the types and duration of hormonal therapy were analyzed.  We 
administered 91 patients with Luteinizing hormone-releasing hormone (LH-RH) agonis,  49 patients with 
anti-androgen (bicaltamide/ﬂ utamide),  and 48 patients with maximum androgen blockade (MAB).  The 
duration of the hormonal therapy was 1ﾝ3 months for 49 patients,  4ﾝ6 months for 59 patients,  7ﾝ9 
months for 40 patients,  10ﾝ12 months for 32 patients,  and over 13 months for 8 patients.  Before the 
initiation of hormonal therapy,  the mean prostate volume was 35.12 ml (11.04ﾝ78.71 ml),  and the aver-
age of prostate volume before and after hormonal therapy was 36.79 ml and 24.79 ml,  respectively (a 
32.4ｵ reduction).  The prostate volume reduction rate was 32.0ｵ for the LH-RH agonist only,  18.1ｵ 
for the anti-androgen only and 41.2ｵ for the MAB.  No statistically signiﬁ cant diﬀ erence was observed 
for the duration of hormonal therapy between 3 groups.  A three-month course of the neoadjuvant 
LH-RH agonist indicated a suﬃ  cient volume reduction eﬀ ectiveness for a large prostate volume.
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patients with clinically localized prostate cancer have 
been treated with I-125 prostate brachytherapy alone 
or brachytherapy with external-beam radiotherapy 
(EBRT) at our hospital and allied institutions.  Acute 
urinary morbidity following brachytherapy has been 
already reported [4].  Neoadjuvant ADT is often used 
before prostate brachytherapy for unfavorable geom-
etry,  urinary obstructive symptoms and higher risk 
pathologic features [5,  6].  Especially unfavorable 
geometries including pubic arch interference are due 
to the fact that the body structure of Japanese males 
may be small and the pelvic bone may be narrow com-
pared with Western-European males.  Moreover,  
Japanese guidelines for the safe administration of 
I-125 brachytherapy has speciﬁ ed that the radioactiv-
ity in the prostate gland after brachytherapy should be 
within 1,300 MBq,  which indicates that a large pros-
tate volume over 40 ml may be a contra-indication for 
brachytherapy as a monotherapy and that the adminis-
tration of neoadjuvant ADT should be considered.  
However ADT as a prostate volume reduction has not 
been well documented,  and no deﬁ nitive indications 
have been established.  The purpose of the present 
study was to evaluate the eﬃ  cacy of neoadjuvant ADT 
as a prostate volume reduction before brachytherapy 
for clinically localized prostate cancer.
Materials and Methods
　 From September 2003 to December 2005,  188 
patients who visited our hospital and allied institu-
tions for the purpose of prostate brachytherapy were 
administrated neoadjuvant ADT.  The reason for the 
neoadjuvant ADT included a suboptimal geometry,  a 
large prostate volume,  pubic arch interference,  uri-
nary symptoms and the need to waiting until I-125 
permanent prostate brachytherapy alone or in combi-
nation with external-beam radiotherapy could be per-
formed.
　 Before and after the administration of neoadjuvant 
ADT,  all patients underwent a transrectal ultrasound 
volumetric study of the prostate gland.  All ultrasound 
studies were obtained with the patients in the dorsal 
lithotomy position using a biplanar ultrasound probe.  
For the volumetric study,  the prostate gland was 
scanned at 5-mm intervals from the proximal seminal 
vesicles/base of the prostate gland to the apex using 
the brachytherapy planning system VariSeed 7.1 
(Varian Medical Systems,  Palo Alto,  CA,  USA) or 
Interplant 3.3 (CMS,  St.  Louis,  MO,  USA).
　 The relationship between the volume reduction of 
the prostate gland and the method and durations of 
ADT were examined in a multivariate analysis.  
Statistical analysis for the diﬀ erences in the prostate 
volume reduction rate between each ADT was per-
formed using the Fisher’s Exact test using Statview 
J5.0 (SAS,  Cary,  NC,  USA).  Diﬀ erences were 
regarded as statistically signiﬁ cant at p values less 
than 0.05.
Results
　 The clinical characteristics of 188 patients are 
shown in Table 1.  The median patient age was 68 
years.  Patients presented with median pretreatment 
PSA levels of 7.88 ng/ml,  a median Gleason score of 
6 and a median pretreatment prostate volume of 
35.12 ml.  Table 2 presents the type and the duration 
of androgen deprivation therapy.  We administrated 
91 patients with Luteinizing hormone-releasing hor-
mone (LH-RH; Leuprolide 3.75 mg or Goserelin 
3.6 mg) agonist,  49 patients with anti-androgen (bical-
tamide 80 mg or ﬂ utamide 375 mg),  and 48 patients 
with maximum androgen blockade (MAB) that was 
achieved by the deprivation of testicular and adrenal 
androgen by simultaneous administration of LH-RH 
and anti-androgen.  The duration of the hormonal 
therapy was 1ﾝ3 months for 49 patients,  4ﾝ6 months 
for 59 patients,  7ﾝ9 months for 40 patients,  10ﾝ12 
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Table 1　 Clinical and pathological characteristics of the patients
Median (range)
Age (years) 68　　 (51ﾝ85)
Pretreatment PSA (ng/ml) 7.88　(0.7ﾝ29.0)
Gleason score 6　　 (4ﾝ9)
Pretreatment prostate volume (ml) 35.12　(11.04ﾝ78.71)
Number of patients (%)
Pretreatment PSA (ng/ml) ＜10 126　(67.0%)
10ﾝ20 57　(30.3%)
＞20 5　( 2.7%)
Gleason score ｦ6 120　(63.8%)
3＋4 36　(19.1%)
4＋3 29　(15.4%)
ｧ8 3　( 1.6%)
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months for 32 patients,  and over 13 months for 8 
patients.  Every patient underwent the prostate 
brachytherapy after the neoadjuvant ADT.  Table 3 
presents the diﬀ erence in the prostate volume before 
and after androgen deprivation therapy.  The average 
of prostate volume before and after hormonal therapy 
was 36.79 ml and 24.79 ml,  respectively (a 32.4ｵ 
reduction,  p＜0.0001).  The prostate volume reduction 
rate was 32.0ｵ in LH-RH agonist only,  18.1ｵ in 
anti-androgen only and 41.2ｵ in MAB (p＜0.0001).  
There were no diﬀ erences between each LHRA agents 
or antiandrogen agent.  We also evaluated the rela-
tionship between the prostate volume reduction rate 
and the duration of hormonal therapy (Fig.  1).  Fig.  
1A shows that 38 patients (41.8ｵ) who received 
LH-RH for 1ﾝ3 months had only a 27.7ｵ prostate 
volume reduction,  22 patients (24.1ｵ) who received it 
for a 4ﾝ6 months duration had a 37.4ｵ reduction,  
and 31 patients (34.1ｵ) who received it for over 7 
months had a 34.7ｵ reduction.  Fig.  1B shows the 
diﬀ erences in the prostate volume after each duration 
of the anti-androgen drug only: 5 patients (10.2ｵ) 
who received it for a 1ﾝ3 months duration had a 
12.5ｵ prostate volume reduction,  19 (38.8ｵ) who 
received it for a 4ﾝ6 months duration had a 22.4ｵ 
reduction and 25 (51.0ｵ) who received it for over 7 
months had a 16.2ｵ reduction.  Fig.  1C shows the 
diﬀ erences in prostate volume after each duration of 
MAB.  Six patients (12.5ｵ) who received it for a 1ﾝ3 
months duration had a 33.9ｵ prostate volume reduc-
tion,  18 patients (37.5ｵ) who received it for a 4ﾝ6 
months duration had a 38.5ｵ reduction,  and 24 
patients (50.0ｵ) who received it for over 7 months 
had a 45.1ｵ prostate volume reduction.  No statisti-
cally signiﬁ cant diﬀ erence was observed between the 
diﬀ erent durations of androgen deprivation therapy.
Discussion
　 Over the past decade,  prostate brachytherapy has 
been increasingly utilized as a deﬁ nitive management 
for clinically localized prostate cancer.  Its results 
have been reported to be as favorable as those in the 
most positive radical prostatectomy series,  with a 
decreased incidence of urinary incontinence and sexual 
dysfunction [7ﾝ10].
　 Neoadjuvant ADT is often used before prostate 
brachytherapy for unfavorable geometry,  urinary 
obstructive symptoms and higher risk pathologic fea-
tures [5,  6].  Wilson reported that neoadjuvant ADT 
is useful in decreasing the size of prostates greater 
than 50 to 60 ml in volume and improving the dosime-
try and technical feasibility of brachytherapy [11].  
Several studies reported that a 3 to 8 month duration 
of neoadjuvant ADT,  including an LH-RH agonist with 
or without an anti-androgen,  results in a prostate vol-
ume reduction of 21ｵﾝ54ｵ [12ﾝ18].  However,  it is 
still unclear what kind of ADT is most eﬀ ective and 
how long the ADT must be administrated for the vol-
ume reduction of the prostate.
　 In the present study,  3 methods of ADT were com-
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Table 2　 Type and duration of androgen deprivation therapy 
(ADT)
Number of patients (%)
Type of ADT LH-RH agonist only 91　(48.4%)
Anti-androgen only 49　(26.1%)
MAB 48　(25.5%)
Duration of ADT  1ﾝ 3　months 49　(26.1%)
 4ﾝ 6　months 59　(31.4%)
 7ﾝ 9　months 40　(21.3%)
10ﾝ12　months 32　(17.0%)
13ﾝ　　months 8　( 4.2%)
LH-RH,  luteinizing hormone-releasing hormone; MAB,  maximum 
androgen blockade.
Table 3　 The diﬀ erence of prostate volume before and after ADT
Type of ADT before ADT after ADT reduction (%) P value
Overall 36.79±15.11 24.79±  9.77 32.4 ＜0.0001
LH-RH only 35.58±12.80 24.18±10.12 32.0 ＜0.0001
Anti-androgen only 26.38±  7.79 21.60±  6.95 18.1 ＜0.0001
MAB 49.70±15.69 29.21±10.15 41.2 ＜0.0001
ADT,  androgen deprivation therapy; LH-RH,  luteinizing hormone-releasing hormone; MAB,  maximum androgen blockade.
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Fig. 1C　 The diﬀ erence of prostate volume after each duration of MAB.
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Fig. 1B　 The diﬀ erence of prostate volume after each duration of Anti-androgen only.
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Fig. 1A　 The diﬀ erence of prostate volume after each duration of LH-RH only. PTS, Patients.
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pared as to the prostate volume reduction.  The overall 
result of average prostate volume reduction was 
32.4ｵ,  which compares favorably with the results of 
previous studies using an LH-RH agonist with or with-
out an anti-androgen.  The volume reduction rate was 
32.0ｵ for the LH-RH agonist only,  18.1ｵ for the 
anti-androgen only and 41.2ｵ for the MAB,  results 
which indicate no statistically signiﬁ cant diﬀ erence.  
The over 6-month duration of MAB showed the great-
est degree of volume reduction (reduction rate 
45.1ｵ),  but there is no statistically signiﬁ cant diﬀ er-
ence between each duration of MAB therapy.  
Therefore,  our data may suggest that a prostate vol-
ume of less than 60 ml may be low enough for the 
administration of a 3-month course of LH-RH only,  
considering the cost and side eﬀ ects of MAB,  which 
can include hot ﬂ ashes,  loss of potency and fatigue 
[19].  Cases of prostate volume greater than 60 ml 
may be contra-indications for brachytherapy with neo-
adjuvant ADT.  If the prostate volume is less than 
50 ml and the patient hopes to maintain erectile func-
tion during the hormonal therapy,  anti-androgen might 
be selected for the volume reduction.
　 We did not consider the overall results of the qual-
ity of life (QOL) after the brachytherapy with or 
without ADT.  Some studies have been reported 
regarding a possible correlation between ADT and 
urinary dysfunction following brachytherapy [20ﾝ23].  
Some of these have indicated an increased risk of uri-
nary retention with ADT [21,  22],  and others have 
indicated that overall QOL and urinary functions do 
not appear to be signiﬁ cantly related to pre-implant 
prostate volume and hormonal therapy [20,  23].  
Since the indication of prostate volume for brachy-
therapy in Japan is smaller than that for Western 
European males,  further investigation is needed to 
conﬁ rm such a relationship between brachytherapy 
with or without neoadjuvant ADT and QOL.
　 Conclusions. Since the prostate volume is an 
important factor for an adequate dose volume histo-
gram in radiation therapy,  neoadjuvant androgen 
deprivation therapy is often used before radiation 
therapy,  especially before brachytherapy in cases of 
unfavorable geometry.  In our study,  a 3-month course 
of neoadjuvant LH-RH agonist monotherapy indicated 
a suﬃ  cient volume reduction eﬀ ectiveness for large 
prostate volumes less than 60 ml.  Anti-androgen 
monotherapy might be selected according to the pros-
tate volume,  urinary symptoms and sexual activity of 
the patient.
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